Clinical trials: Glucagon
Hyperinsulinemic Hypoglycemia
Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery
This is a double-blind, placebo-controlled Phase 2 study to assess the efficacy, safety and tolerability of Glucagon RTU when administered to subjects with a history of bariatric surgery during episodes of post-postprandial…
- Trial name
- NCT03770637
- Testing
- Glucagon RTU
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Xeris Pharmaceuticals
Triglycerides, Weight Gain Trajectory
Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
The goal of this clinical trial is to learn if drug RDX-002 works to treat high levels of fat (known as triglycerides, or TGs) in the blood in adults. It will also learn about the safety of drug RDX-002.
- Conditions
- Triglycerides, Weight Gain Trajectory, Cholesterol, Elevated
- Trial name
- NCT06640972
- Testing
- RDX-002
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Response Pharmaceuticals
Healthy Volunteers
The Effect of LY2409021 on Blood Sugar Levels When Glucagon Levels Are Increased in Healthy Male Participants
This is a study to measure the effect that various doses of LY2409021 have on blood sugar levels and on the amount of glucose released by the liver, when glucagon is given to increase these.
- Trial name
- NCT01606423
- Testing
- LY2409021
- Where
- Singapore
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM
To compare efficacy, safety and durability of combination therapy with pioglitazone plus GLP-1 RA versus basal bolus insulin in poorly controlled T2DM patients on metformin plus sulfonylurea
- Trial name
- NCT02887625
- Testing
- Pioglitazone plus exenatide, insulin glargine and insulin aspart
- Where
- Qatar
- Volunteers
- 410 people
- Sponsor
- Dr. Muhammad Abdulghani
Diabetes Mellitus, Type 2
Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes
This mechanistic study is designed to investigate the effect of vildagliptin on the sensitivity of the a-cell to glucose under hypoglycemic conditions in patients with type 2 diabetes (T2DM).
- Trial name
- NCT00390520
- Testing
- Vildagliptin
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Novartis
Hypoglycemia
G-Pen™ for Hypoglycemia Rescue in T1D Patients
This is an open-label, exploratory pilot study in patients with T1D. The study will involve two daytime clinical research center visits 7-14 days apart.
- Trial name
- NCT02423980
- Testing
- Glucagon
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Xeris Pharmaceuticals
Healthy
A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults
The main purpose of this study was to evaluate the safety and tolerability of nasal glucagon (NG). The study drug was delivered into the participant's nostril (intranasally) or was given as an injection just under the skin…
- Trial name
- NCT02778113
- Testing
- Nasal Glucagon, Glucagon
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years.
- Trial name
- RescuiNGkids (NCT04992312)
- Testing
- Glucagon Nasal Powder [Baqsimi]
- Where
- 8 sites in United States
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
The purpose of this trial is to examine the efficacy and safety of once-weekly LY2189265 (dulaglutide) in participants with type 2 diabetes mellitus taking an oral antihyperglycemic medication (OAM).
- Trial name
- NCT01584232
- Testing
- LY2189265, Insulin glargine, Sulfonylureas (SU)
- Where
- 15 sites in Japan
- Volunteers
- 361 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a randomized, double-blind, placebo controlled, parallel group study, which aims to provide data on efficacy, safety and pharmacokinetics (PK) of multiple dose levels of HDM1002 tablets in adults with type 2 diabetes…
- Trial name
- NCT06481085
- Testing
- HDM1002 50 mg, HDM1002 100 mg, HDM1002 200 mg
- Where
- 31 sites in China
- Volunteers
- 324 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus
This Phase IIIb, randomized, double-blind, parallel-group, placebo-controlled, multicenter, treat-to-target study of 26 weeks treatment duration will evaluate the efficacy and safety of once-weekly albiglutide versus placebo as…
- Trial name
- NCT02229240
- Testing
- Albiglutide
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients
Primary Objectives: To assess in overweight to obese T2DM patients: The glucagon receptor occupancy of SAR425899 at two dose levels in the human liver with positron-emission tomography (PET) imaging using…
- Trial name
- NCT03350191
- Testing
- SAR425899, [68Ga] Ga-DO3A-VS-Cys40-Tuna-2 (glucagon receptor tracer), [68Ga] Ga-DO3A-VS-Cys40-Exendin-4 (GLP-1 receptor tracer)
- Where
- Sweden
- Volunteers
- 13 people
- Sponsor
- Sanofi
Hypoglycemia
Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia
In this study, participants with Type 1 diabetes received insulin through an infusion into a vein to reduce their blood glucose, and then received nasal glucagon (NG) or glucagon for injection under the skin, and their blood…
- Trial name
- AMG102 (NCT01556594)
- Testing
- Nasal Glucagon 1 mg, Nasal Glucagon 2 mg, SC Glucagon
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin.
- Trial name
- SURPASS-5 (NCT04039503)
- Testing
- Tirzepatide
- Where
- 48 sites in United States, Czechia and 6 more
- Volunteers
- 475 people
- Sponsor
- Eli Lilly and Company
Healthy Adult Subject
A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects
The purpose of this study is to characterize the effect of rifampicin and itraconazole on the PK of single dose of HDM1002 in healthy adult subjects.
- Trial name
- NCT06562088
- Testing
- HDM1002 and rifampicin, HDM1002 and itraconazole
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
This Phase IIIb, randomized, open-label, parallel group, active control, multicenter, treat to-target study of 26 weeks' treatment duration will evaluate the efficacy and safety of once-weekly albiglutide as replacement of…
- Trial name
- NCT02229227
- Testing
- Albiglutide, Insulin Glargine and Insulin Lispro
- Where
- 157 sites in United States, Brazil and 12 more
- Volunteers
- 814 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1
Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
The purpose of this study is to assess the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and safety of 3 milligrams (mg) glucagon (glucagon nasal powder) administered nasally compared with commercially available…
- Trial name
- NCT01994746
- Testing
- Nasal Glucagon, Intramuscular Glucagon
- Where
- 8 sites in United States
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 1
The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate if liraglutide adjunct to insulin treatment changes the glucagon response during hypoglycaemia in subjects with type 1 diabetes compared with conventional…
- Trial name
- NCT01536665
- Testing
- liraglutide
- Where
- Austria
- Volunteers
- 45 people
- Sponsor
- Novo Nordisk A/S
Healthy
A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
The main purpose of this study is to assess the effect of carbamazepine on the amount of orforglipron in the bloodstream and how long it takes the body to get rid of orforglipron when given orally in healthy study participants.
- Trial name
- NCT06370728
- Testing
- Orforglipron, Carbamazepine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Weight Management
A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity
The aim of the study is to evaluate the efficacy and safety of XW003 versus placebo in adults with overweight or obesity
- Trial name
- NCT05813795
- Testing
- Ecnoglutide Low Dosage, Ecnoglutide Medium Dosage, Ecnoglutide High Dosage
- Where
- China
- Volunteers
- 664 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.